For research use only
| Cat No. | ABC-X0217C |
| Product Type | Overexpression Stable Cell Lines |
| Cell Type | Lymphocytes |
| Species | Human |
| Host Cell | BAF3 |
| Source Organ | Lymphatic |
| Disease | Normal |
| Storage | Liquid Nitrogen |
Human BCR_ABL (F317L) BAF3 Cell Line is specifically engineered for studying drug resistance mechanisms in leukemia and targeted therapy development.
The Human BCR_ABL (F317L) BAF3 Cell Line was generated via lentiviral transduction to stably express the human BCR_ABL gene with the F317L mutation in murine BAF3 cells. This modification enables IL-3-independent proliferation, making it a robust model for kinase inhibitor screening.
Target
BCR_ABL is an oncogenic fusion gene critical in chronic myeloid leukemia. The F317L mutation is associated with resistance to second-generation tyrosine kinase inhibitors. AcceGen offers generation of stable overexpression cell lines targeting any gene of your interest. Polyclonal or monoclonal is optional based on customers’ research needs.
| Species | Human |
| Cat.No | ABC-X0217C |
| Product Category | Transfected Stable Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Lymphocytes |
| Growth Mode | Suspension |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 °C, 5% CO2 |
| Source Organ | Lymphatic |
| Disease | Normal |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Overexpression Stable Cell Lines |
| Host Cell | BAF3 |
| Quality Control | All cells test negative for mycoplasma, bacteria, yeast, and fungi. |
Ideal for studying resistance mechanisms and drug efficacy in targeted leukemia therapies, especially those targeting ABL kinase domain mutants.